$SVRA
Savara Inc

2018 Q4 Form 10-Q Financial Statement

#000156459018028021 Filed on November 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.250M $3.150M $2.670M
YoY Change 21.72% 126.62% 38.34%
% of Gross Profit
Research & Development $9.860M $9.509M $6.440M
YoY Change 53.11% 91.48% 7950.0%
% of Gross Profit
Depreciation & Amortization $140.0K $130.0K $90.00K
YoY Change 55.56% 42.86% -156.25%
% of Gross Profit
Operating Expenses $13.25M $12.78M $9.200M
YoY Change 44.02% 95.38% 353.2%
Operating Profit -$13.25M -$12.78M -$9.296M
YoY Change 42.51% 95.38% 129.87%
Interest Expense $90.00K $111.0K -$120.0K
YoY Change -175.0% -59.93% -14.29%
% of Operating Profit
Other Income/Expense, Net $140.0K $224.0K
YoY Change
Pretax Income -$13.02M -$12.56M -$9.310M
YoY Change 39.85% 81.14% 10.31%
Income Tax $2.500M $0.00 -$10.00K
% Of Pretax Income
Net Earnings -$10.51M -$12.56M -$6.502M
YoY Change 61.7% 84.25% 63.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$292.5K -$364.3K -$225.9K
COMMON SHARES
Basic Shares Outstanding 35.13M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.8M $112.0M $94.30M
YoY Change 17.5% 110.13% 603.73%
Cash & Equivalents $24.30M $24.95M $22.12M
Short-Term Investments $86.50M $87.10M $72.20M
Other Short-Term Assets $800.0K $1.600M $2.500M
YoY Change -68.0% -11.11% 212.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $113.3M $114.7M $97.86M
YoY Change 15.82% 106.75% 570.3%
LONG-TERM ASSETS
Property, Plant & Equipment $522.0K $605.0K $925.0K
YoY Change -43.57% 0.83% 15.63%
Goodwill $26.92M $26.96M $27.08M
YoY Change -0.61%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $131.0K $1.292M $131.0K
YoY Change 0.0% 29.2%
Total Long-Term Assets $38.94M $40.38M $61.76M
YoY Change -36.95% -36.31% 331.92%
TOTAL ASSETS
Total Short-Term Assets $113.3M $114.7M $97.86M
Total Long-Term Assets $38.94M $40.38M $61.76M
Total Assets $152.3M $155.1M $159.6M
YoY Change -4.6% 30.47% 452.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.879M $3.240M $2.784M
YoY Change 39.33% 90.59% 456.8%
Accrued Expenses $3.375M $3.912M $2.966M
YoY Change 13.79% -4.59% 18.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.100M $300.0K
YoY Change -100.0% 1266.67% -25.0%
Total Short-Term Liabilities $7.254M $11.20M $6.000M
YoY Change 20.9% 83.61% 23.3%
LONG-TERM LIABILITIES
Long-Term Debt $24.50M $11.40M $15.10M
YoY Change 62.25% -24.0% 277.5%
Other Long-Term Liabilities $70.00K $12.20M $12.10M
YoY Change -99.42% 2.52% 8.04%
Total Long-Term Liabilities $70.00K $23.60M $27.20M
YoY Change -99.74% -12.27% 78.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.254M $11.20M $6.000M
Total Long-Term Liabilities $70.00K $23.60M $27.20M
Total Liabilities $44.07M $37.30M $40.32M
YoY Change 9.3% -15.69% 92.47%
SHAREHOLDERS EQUITY
Retained Earnings -$129.7M -$68.20M
YoY Change 90.2% 77.58%
Common Stock $237.7M $186.6M
YoY Change 27.44% 5875.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.2M $117.9M $119.3M
YoY Change
Total Liabilities & Shareholders Equity $152.3M $155.1M $159.6M
YoY Change -4.6% 30.45% 451.7%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q4
OPERATING ACTIVITIES
Net Income -$10.51M -$12.56M -$6.502M
YoY Change 61.7% 84.25% 63.82%
Depreciation, Depletion And Amortization $140.0K $130.0K $90.00K
YoY Change 55.56% 42.86% -156.25%
Cash From Operating Activities -$10.50M -$8.760M -$9.470M
YoY Change 10.88% 6.31% -69.54%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$10.00K -$440.0K
YoY Change -86.36%
Acquisitions
YoY Change
Other Investing Activities $930.0K -$35.70M -$38.62M
YoY Change -102.41% 6.76% -353.91%
Cash From Investing Activities $870.0K -$35.71M -$39.06M
YoY Change -102.23% 6.79% -356.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.090M 45.81M 50.76M
YoY Change -82.09% 10553.49% 1898.43%
NET CHANGE
Cash From Operating Activities -10.50M -8.760M -9.470M
Cash From Investing Activities 870.0K -35.71M -39.06M
Cash From Financing Activities 9.090M 45.81M 50.76M
Net Change In Cash -540.0K 1.340M 2.230M
YoY Change -124.22% -103.25% -116.72%
FREE CASH FLOW
Cash From Operating Activities -$10.50M -$8.760M -$9.470M
Capital Expenditures -$60.00K -$10.00K -$440.0K
Free Cash Flow -$10.44M -$8.750M -$9.030M
YoY Change 15.61% 6.19% -70.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35128771
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24946000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22121000
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
87102000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
72192000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3551000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
97864000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
925000
CY2018Q3 svra In Process Research And Development
InProcessResearchAndDevelopment
11520000
CY2017Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
33626000
CY2017Q4 us-gaap Goodwill
Goodwill
27082000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1292000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
us-gaap Paid In Kind Interest
PaidInKindInterest
83000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
111000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
332000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
114745000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
605000
CY2018Q3 us-gaap Assets
Assets
155124000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3240000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2697000
CY2018Q3 us-gaap Goodwill
Goodwill
26962000
us-gaap Share Based Compensation
ShareBasedCompensation
350000
dei Entity Small Business
EntitySmallBusiness
false
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3912000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8410000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
21692000
us-gaap Depreciation
Depreciation
387000
us-gaap Depreciation
Depreciation
272000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7402000
CY2018Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
12079000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
11948000
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
297000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
186522000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
958000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68203000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
119309000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159628000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30509522
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30509522
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-277000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-106000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1038000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
87000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1816000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3359000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24117000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-824000
us-gaap Net Income Loss
NetIncomeLoss
-23293000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12560000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-105000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21955000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13770032
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45792000
svra Issuance Of Common Stock Upon At The Market Sales Net
IssuanceOfCommonStockUponAtTheMarketSalesNet
493000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
svra Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
19000
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
995000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2792000
us-gaap Profit Loss
ProfitLoss
-51002000
us-gaap Profit Loss
ProfitLoss
-23293000
svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-52000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18764000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3442000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
88104000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
33443000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
64346000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
9351000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14488000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30062000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14894000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3569000
svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-280000
svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
131000
svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
2108000
us-gaap Paid In Kind Interest
PaidInKindInterest
395000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
995000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
301000
svra Accretion On Discount To Short Term Investments And Convertible Promissory Notes
AccretionOnDiscountToShortTermInvestmentsAndConvertiblePromissoryNotes
546000
svra Accretion On Discount To Short Term Investments And Convertible Promissory Notes
AccretionOnDiscountToShortTermInvestmentsAndConvertiblePromissoryNotes
34000
us-gaap Share Based Compensation
ShareBasedCompensation
2792000
svra Issuance Of Call Option Derivative
IssuanceOfCallOptionDerivative
344000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4555000
svra Increase Decrease In Grant And Award Receivable
IncreaseDecreaseInGrantAndAwardReceivable
-400000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1393000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
785000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-969000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1272000
svra Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-23000
svra Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-14000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1391000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
143000
svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
19000
svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
384000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
45792000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
39522000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
493000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3567000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
257000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
460000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46097000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55333000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-67000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2825000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6440000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22121000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13373000
svra Non Cash Extinguishment And Derecognition Of Put Options
NonCashExtinguishmentAndDerecognitionOfPutOptions
2202000
svra Shares Issued In Connection Of Business Combination And Assumed Equity Awards
SharesIssuedInConnectionOfBusinessCombinationAndAssumedEquityAwards
35846000
svra Non Cash Accretion Of Redeemable Convertible Preferred Stock
NonCashAccretionOfRedeemableConvertiblePreferredStock
578000
svra Non Cash Beneficial Conversion Feature
NonCashBeneficialConversionFeature
404000
svra Common Stock Issued For In Process Research And Development Net
CommonStockIssuedForInProcessResearchAndDevelopmentNet
995000
us-gaap Interest Paid Net
InterestPaidNet
1038000
CY2017Q2 svra Business Combination Consideration Fair Value Of Equity
BusinessCombinationConsiderationFairValueOfEquity
2729000
CY2017Q2 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
35846000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
3442000
CY2017Q2 svra Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
283000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
21692000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
2396000
CY2017Q2 svra Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDebt
3407000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
7375000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
12239000
CY2017Q2 us-gaap Goodwill
Goodwill
23607000
CY2017Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
35846000
us-gaap Interest Paid Net
InterestPaidNet
359000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management&#8217;s estimates include those related to the accrual of research and development costs, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging. The Company places its cash and cash equivalents with a limited number of high-quality financial institutions and at times may exceed the amount of insurance provided on such deposits. </p></div>
CY2018Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
292000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
11412000
CY2018Q3 svra Contingent Milestones Or Co Development Commitments Incurred
ContingentMilestonesOrCoDevelopmentCommitmentsIncurred
0
CY2017Q4 svra Contingent Milestones Or Co Development Commitments Incurred
ContingentMilestonesOrCoDevelopmentCommitmentsIncurred
0
CY2018Q3 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
891000
CY2017Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
834000
CY2018Q3 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
1067000
CY2017Q4 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
2129000
CY2017Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
196000
CY2018Q3 us-gaap Prepaid Insurance
PrepaidInsurance
289000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2018Q3 svra Forward Currency Exchange Derivative Current
ForwardCurrencyExchangeDerivativeCurrent
4000
CY2017Q4 svra Forward Currency Exchange Derivative Current
ForwardCurrencyExchangeDerivativeCurrent
40000
CY2018Q3 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
154000
CY2017Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
194000
CY2018Q3 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2946000
CY2017Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1308000
CY2018Q3 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
578000
CY2017Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
323000
CY2018Q3 svra Accrued Compensation
AccruedCompensation
388000
CY2017Q4 svra Accrued Compensation
AccruedCompensation
1328000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7000
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
87122000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
72238000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
87102000
CY2017Q1 svra Lease Agreement Date
LeaseAgreementDate
2014-06-19
CY2017Q1 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
44000
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
13000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
72192000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q2 svra Business Combination Consideration Fair Value Shares Outstanding
BusinessCombinationConsiderationFairValueSharesOutstanding
33117000
CY2017 svra Number Of Tranches
NumberOfTranches
2
CY2018Q3 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
900000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2018Q3 svra Principal Payments Of Debt And End Of Term Charge Current
PrincipalPaymentsOfDebtAndEndOfTermChargeCurrent
3750000
CY2018Q3 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
11601000
CY2018Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
54000
CY2018Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
190000
CY2018Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018Q3 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
201000000
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4468840
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4072391
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1665170
CY2017Q1 svra Operating Lease Office Space
OperatingLeaseOfficeSpace
13707
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
6000
CY2017Q1 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.030
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q4 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
svra Employment Agreement Description
EmploymentAgreementDescription
Upon termination without cause, and not as a result of death or disability, each of such officers is entitled to receive a payment of base salary for twelve months and pro-rated portion of their unpaid bonus following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or for good reason within twelve months following a change in control, each of such officers is entitled to receive a payment of base salary for eighteen months and one-hundred percent of their unpaid bonus following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer and will also be entitled to certain acceleration of such officer's outstanding unvested options at the time of such termination
svra Percentage Of Unpaid Bonus To Be Paid Upon Termination
PercentageOfUnpaidBonusToBePaidUponTermination
1.00
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1988000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
114000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2792000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4472887
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3629158

Files In Submission

Name View Source Status
0001564590-18-028021-index-headers.html Edgar Link pending
0001564590-18-028021-index.html Edgar Link pending
0001564590-18-028021.txt Edgar Link pending
0001564590-18-028021-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10q_20180930.htm Edgar Link pending
svra-20180930.xml Edgar Link completed
svra-20180930.xsd Edgar Link pending
svra-20180930_cal.xml Edgar Link unprocessable
svra-20180930_def.xml Edgar Link unprocessable
svra-20180930_lab.xml Edgar Link unprocessable
svra-20180930_pre.xml Edgar Link unprocessable
svra-ex311_11.htm Edgar Link pending
svra-ex312_9.htm Edgar Link pending
svra-ex321_6.htm Edgar Link pending